Some big issues remain for HeartMate 3
MOMENTUM 3
Last year, HeartMate 3, a fully magnetically levitated centrifugal-flow circulatory pump, showed better outcomes at 6 months than did HEARTMATE 2, an axial-flow pump, in the primary results of MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3).
Most impressive was the complete elimination of pump thrombosis in the patients with the smaller HeartMate 3 device. On Sunday, the 2-year results will reveal whether longer-term use of the novel technology will carry similar benefits, Dr. Kates said.
MOMENTUM 3 will be presented at the third Late-Breaking Clinical Trials session, at 10:45-11:45 a.m., in the Main Tent (Hall C) by Mandeep R. Mehra, MD, professor of medicine at Harvard Medical School and medical director of the Heart and Vascular Center of Brigham and Women’s Hospital, both in Boston.